It has been suggested that pancreatic ductal hypertension, secondary to pancreatic outflow obstruction, is a cause of pain in chronic pancreatitis. This study investigated the effect of inhibiting pancreatic secretion with octreotide in chronic pancreatitis pain. Ten patients with chronic alcoholic pancreatitis and severe daily pain were included in an intraindividual double blind crossover study. All patients received octreotide (3 X 100 jig/day subcutaneously) and placebo (3X0.90% saline solution subcutaneously) for three days at random. Between both treatment phases a two day washout period was interposed. Intensity of pain (visual analogue scale) and analgesic consumption were carefully registered. Pancreatic secretion was monitored daily by measuring faecal chymotrypsin concentration. It was found that during the administration of octreotide, pancreatic secretion was strongly inhibited (faecal chymotrypsin mean (SD) 1.7 (0.6) UIg) with respect to placebo (9.6 (4.2) UIg) and washout (7.6 (3.1) UIg) periods (p<0001). Pain score (29.6 (4.5) v 28.7 (5.8)) and consumption of analgesics were no different during the octreotide and placebo periods. It is concluded that short term inhibition of pancreatic secretion does not result in pain relief in patients with chronic pancreatitis. This finding is in contrast with the hypothesis that outflow obstruction of pancreatic secretion with consequent ductal hypertension is an important cause of severe persistent pain in chronic pancreatitis. (Gut 1995; 36: 450-454) 
received octreotide (3 X 100 jig/day subcutaneously) and placebo (3X0.90% saline solution subcutaneously) for three days at random. Between both treatment phases a two day washout period was interposed. Intensity of pain (visual analogue scale) and analgesic consumption were carefully registered. Pancreatic secretion was monitored daily by measuring faecal chymotrypsin concentration. It was found that during the administration of octreotide, pancreatic secretion was strongly inhibited (faecal chymotrypsin mean (SD) 1.7 (0.6) UIg) with respect to placebo (9.6 (4.2) UIg) and washout (7.6 (3.1) UIg) periods (p<0001). Pain score (29.6 (4.5) v 28.7 (5.8)) and consumption of analgesics were no different during the octreotide and placebo periods. It Relapsing as well as continuous pain in chronic pancreatitis vary considerably concerning localisation, irradiation, and temporal relation with food intake. This heterogeneity may explain why several different hypotheses have been proposed to explain the pathogenesis of pain in chronic pancreatitis.
Two mechanisms are commonly suggested for the generation of pain in chronic pancreatitis. These are ductal and parenchymal hypertension,-6 and inflammatory parenchymal changes with participation of pancreatic nerves.7 8 According to these hypotheses, therapeutic procedures for pain in chronic pancreatitis have focused on decompression of the hypertensive ductal/parenchymal structures or on resection of the inflammatory mass.9 10 A therapeutic approach of decreasing ductal hypertension has been more recently attempted by high doses of exogenous pancreatic enzymes.11 12 As exogenous pancreatic enzymes inhibit pancreatic secretion by a negative feedback, pain relief is expected to occur in cases with increased intraductal and parenchymal pressure. Most therapeutic studies, however, failed to give credit to this rationale or provided inconclusive data. '3 14 Different doses of exogenous pancreatic enzymes may explain the inconsistency in results among studies, and the lack of control of whether inhibition of pancreatic secretion was achieved in individual patients leaves this issue unsettled.
To further contribute to the understanding of the pathogenesis and treatment of pain in chronic pancreatitis, we tested the role of ductal hypertension by giving a potent inhibitor of pancreatic secretion, the somatostatin analogue octreotide.15 16 Before starting treatment, patients received a pain protocol and were carefully instructed how to register pain on an ordinary scale. The scale on this protocol included five categories of pain intensity, 1 =no, 2=slight, 3 =moder-ate, 4 = severe, 5= severe pain requiring analgesics. Patients were requested to record the level of pain they experienced every hour except during the hours of sleep. During the day the patients were interviewed every four hours and their scales were checked to ensure they had registered their pain. On the protocol all analgesics required by the patients were recorded. As some patients, before entering the study, were receiving tilidin HCI 50 mg combined with naloxone 4 mg=0.72 ml equivalent to 20 drops (Valoron N, purchased from Godecke) some were receiving tramadol HC1 50 mg= 1 ml equivalent to 20 drops therapy (Tramal purchased from Gruinenthal), they maintained their usual analgesic drugs, on request, during the study period. The amount of analgesic treatment required was recorded as drop number per day. Patients remained in hospital during the study. After a two day observation period patients were randomly allocated to an intraindividual crossover treatment with octreotide and placebo for three days. Octreotide 100 pug and placebo (saline solution 0.9%) were subcutaneously injected every eight hours. Between the two different treatments, a washout period of two days was included. Four patients with main pancreatic duct lithiasis continued the treatment with octreotide (3 X 100 ,ug/day subcutaneous) for two (n= 2) or three months (n= 2).
Blood and faecal samples were taken every morning for determination of serum amylase, pancreatic amylase, trypsin and lipase, and faecal chymotrypsin. Serum them experienced the most severe pain two to three hours after meals, four patients had maximum pain during the night, and four had an absolutely irregular pain cycle. Intensity of pain was no different in either the prestudy, placebo or octreotide treatment phase (Fig 1) . There was also no reduction in the requirement of analgesics during treatment with octreotide compared with placebo (Fig 1) . There was, however, a reduction in the consumption of analgesics during each of the days in hospital compared with the consumption of analgesics at home (20 (10) drops v 40 (10) drops, respectively, p<0.01). No therapeutic benefit with octreotide was seen when patients with postprandial pain were separately analysed. In the subgroup of patients with main pancreatic duct stones, no benefit was obtained by prolonged octreotide treatment.
PANCREATIC FUNCTION
Faecal chymotrypsin was significantly inhibited in all patients during the three days of octreotide treatment (Fig 2) . Faecal chymotrypsin concentrations during octreotide treatment (1.69 (0.58) U/g) pointed to an almost complete absence of pancreatic secretion.
There was no influence of octreotide on basal serum concentrations of pancreatic enzymes after an overnight fast (Table II) . (3 x 100 ,ug/day) does not influence severe pain in chronic pancreatitis. In the short term, octreotide in the dose used was previously shown to inhibit pancreatic secretion by 80% in healthy volunteers. 16 The almost complete abolishment of pancreatic secretion as shown by the measurement of faecal chymotrypsin is, by physical law, accompanied with a drop in intraductal pressure. The lack of pain improvement by inhibiting pancreatic secretion seems to be a strong argument against theories that support a role of increased ductal and parenchymal pressures in the pathogenesis of pain in chronic pancreatitis.4-6 11 12 This finding is in contrast with two previous studies, in which surgical decompression of the ductal system was followed by a reduction in ductal and intraparenchymal pressure and an improvement in pain.5 6 Both of these studies, however, do not permit differentiation 3 At this stage, however, the pancreatic gland is completely fibrotic and the inflammatory activity is greatly reduced or even absent. The findings of this study favour the assumption that chronic pain is probably generated by the inflammatory process within the pancreas and the peripancreatic region. 7 The strict inclusion of patients with daily and severe pain in our study and not ofpatients with sporadic bouts of pain could be used as an argument for the therapeutic ineffectiveness obtained by the These arguments challenge more recent data showing significant pain relief after interventional endoscopic procedures in which a stent was placed in, or stones removed from, the main pancreatic duct. [25] [26] [27] In the absence of proper controls, the effect of such endoscopic interventions cannot be defined as causal for pain relief. If duct obstruction is the cause of chronic pain in chronic pancreatitis then patients with stones in the main pancreatic duct should respond with relief of symptoms to a treatment that inhibits pancreatic secretion. Such a procedure could help to identify those patients who would eventually respond favourably to an endoscopic or surgical drainage procedure and may be worthwhile testing in a future trial.
Dependency on analgesic drugs could account for the lack of therapeutic benefit in some of our patients. The fact that all but two patients could at least temporarily stop drinking and that the analgesic drugs had not been taken for more than three continuous months, with periods of intermission, may reduce the strength of this argument.
The finding that prolonged treatment with octreotide in four patients with chronic pancreatitis and stones in the main pancreatic duct failed to relieve pain is a further, though weaker, argument against the theory of ductal hypertension in the pathogenesis of pain. Prolonged treatment with octreotide has been reported to lead to pain relief in some patients with chronic pancreatitis,28 29 but it is questionable whether the inhibitory effect of pancreatic secretion may persist over time because of the reported tachyphylaxis of the drug.30 Whether mechanisms other than inhibition of pancreatic secretion may account for the effect of octreotide in relieving pain on a longterm basis and whether the length of treatment should be extended is worthwhile testing in differently designed intervention studies.
In summary, the subset of patients with chronic permanent or severe daily pain has no benefit from short term treatment with octreotide. This finding does not support the hypothesis of ductal hypertension as a cause of pain in those patients with chronic pancreatitis. Whether patients with relapsing pain may benefit from octreotide has to be tested in a study using longterm octreotide treatment.
